RAP 0.00% 20.5¢ resapp health limited

And perhaps also another "potential" perspective to consider:...

  1. 35 Posts.
    lightbulb Created with Sketch. 14
    And perhaps also another "potential" perspective to consider:
    (i) Patient is presumed clear of infection from initial consultation (tele-health or in person) based on other products / existing approaches.
    (ii) Condition of the patient deteriorates and they end up in an ER.
    (ii) Doctor in the ER then rapidly diagnoses respiratory infection using ResApp and proper and prompt treatment is given (as expanding and implementing ResApp in emergency room settings was one of the many reasons for the recent CR...).
    (iv) Medical industry (and consumers) realise (hopefully) the easiness and effectiveness of ResApp as a frontline diagnostic tool, thus avoiding timely, dangerous and avoidable misdiagnosis.
    Just another perspective/scenario to consider....
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.